荃信生物1732万股H股上市申请获批

财中社
14 Mar

3月14日,荃信生物(02509)发布公告,宣布公司已获得香港联合交易所对1732万股H股的上市批准。此次上市申请是基于公司于2024年10月28日和2025年1月21日的公告,涉及中国证监会受理的H股全流通申请。根据公告,参与股东在转换及上市后将合计持有公司已发行H股总数的约7.80%。具体而言,裘霁宛持有1000万股H股,占比4.5%;泰州健鑫创业投资有限公司持有375万股,占比1.69%;...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10